Loading
Apellis Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Nov 2021.
Apellis Pharmaceuticals, Inc.: what insiders have been doing
Apellis Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Apellis Pharmaceuticals, Inc. logged 70 filings by 18 insiders.
The flow runs one way only: 27 sales worth €2.4M, from 8 insiders, and no purchase. One trade stands out by size: a sale of €507k from Francois Cedric, disclosed on 23 January 2026.
Compared with its exchange (5,814 companies, median 19 filings), a count of 70 filings is above the norm. Our records for Apellis Pharmaceuticals, Inc. go back to 2021, with 1 purchase and 204 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.00 bn USD and net income of 22.4 m USD.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
562
Thresholds
n/a
Buy Volume
€9M
1 ops. · all time
Sell Volume
€59M
204 ops. · all time
Who traded when
BuySaleDavid O. Watson16 sales
James George Chopas9 sales
Mark Jeffrey DeLong9 sales
Cedric Francois8 sales
Nur Nicholson7 sales
Pascal Deschatelets7 sales
+6 other insiders
Since the insiders bought
- +17.0%Entry US$43.54 · Close at T+365 US$50.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Apellis Pharmaceuticals, Inc. Hold (neutral), based on 13 analysts. Average price target: US$40.92.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,987 of 24,148 companies
49.4
score / 100
Value39
Quality60
FCF yld0.9%
Earn yld0.4%
EV/EBITDA·
ROE46%
Gross mgn90%
Net mgn2.2%
Debt/EBITDA6.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$41.03
Analyst consensus
13 analystsHold
US$40.00Target US$40.92(-0%)US$41.00
Income statement
RevenueUS$1B
Gross profitUS$901.5M90% margin
EBITDAUS$70M7% margin
Net incomeUS$22.4M12.1% margin
Valuation
PER (trailing)38.3x
PER (forward)-130.5x
P/Book12.6x
Beta-0.25
Balance sheet & cash
Market capUS$5.3B
Total debtUS$474.4M
Free Cash FlowUS$45M
Debt / Equity115%
Profitability & ownership
ROE46.0%
ROA10.9%
% insiders11.4%
% institutions110.4%
Last declaration on 14 May 2026
Declarations562 total
116,338 sharesCommon StockSEC:0001193125-26-224604:0
14,312 sharesCommon StockSEC:0001193125-26-224624:0
30,666 sharesCommon StockSEC:0001193125-26-224618:0
127,804 sharesCommon StockSEC:0001193125-26-224589:0
140,945 sharesCommon StockSEC:0001193125-26-224615:0
86,525 sharesCommon StockSEC:0001193125-26-224577:0
107,024 sharesCommon StockSEC:0001193125-26-224620:0
161,567 sharesCommon StockSEC:0001193125-26-224633:0
1,177,222 sharesCommon StockSEC:0001193125-26-224609:0
65,955 sharesCommon StockSEC:0001193125-26-224627:0
425,968 sharesCommon StockSEC:0001193125-26-224579:0
384,989 sharesCommon StockSEC:0001193125-26-224611:0
17,051 sharesCommon StockSEC:0001193125-26-224601:0
25,666 sharesCommon StockSEC:0001193125-26-224606:0
114,591 sharesCommon StockSEC:0001193125-26-224597:0
24,444 sharesCommon StockSEC:0001193125-26-224585:0
144,517 sharesCommon StockSEC:0001193125-26-224583:0
25,666 sharesCommon StockSEC:0001193125-26-224592:0
900 shares0Common StockSEC:0001492422-26-000105:0
11,096 shares0Common StockSEC:0001193125-26-163917:1
11,096 shares0Common StockSEC:0001193125-26-163917:0
5,750 shares0Common StockSEC:0001492422-26-000099:0
64,869 shares0Common StockSEC:0001193125-26-106090:0
14,312 shares0Common StockSEC:0001492422-26-000092:0
368 shares@ US$22.15370.3% of flowCommon StockSEC:0001492422-26-000083:0
25 of 562 declarations
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is a U.S.-based biopharmaceutical company focused on complement biology, with a particular emphasis on the C3 protein, a central node in the immune complement cascade. Founded in 2009 and incorporated in Delaware, the company is headquartered in Waltham, Massachusetts, in the United States. For French-speaking investors, Apellis should be viewed as a specialty biotech rather than a broad-based pharmaceutical group: its value proposition rests on scientific differentiation, regulatory execution, and the gradual expansion of a small number of high-value assets.
Apellis’ corporate history is tied to the development of complement-inhibiting therapies in an area that had long been underexploited. Since its inception in 2009, the company has built a platform designed to control overactivation of the complement system, thereby reducing damage to healthy cells and tissues. That scientific focus has enabled Apellis to establish itself as an early mover in C3-targeted medicine, with two first-in-class commercial products forming the core of its business.
Read moreShow less
Its lead ophthalmology product is SYFOVRE (pegcetacoplan injection), approved for geographic atrophy, an advanced form of age-related macular degeneration and a major cause of irreversible vision loss. The second major franchise is EMPAVELI (pegcetacoplan), originally developed for paroxysmal nocturnal hemoglobinuria and subsequently expanded into rare kidney diseases. In July 2025, the FDA approved EMPAVELI as the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, broadening the commercial and clinical scope of the asset. Together, these two franchises give Apellis a more diversified revenue base than many mid-cap biotechs, although the company remains materially dependent on a limited number of products.
From a competitive standpoint, Apellis operates in high-unmet-need, specialized markets where clinical differentiation matters more than scale. In geographic atrophy, SYFOVRE is positioned as a leading treatment option, while EMPAVELI has established itself as a first-mover therapy in rare complement-driven kidney diseases. This makes the company strategically relevant in both retina and rare disease markets, with a profile that blends commercial-stage execution and pipeline optionality. Apellis also maintains an international footprint, with offices in the United States, Switzerland, Germany, and Australia, supporting both development and commercialization outside its home market.
Recent highlights include the July 2025 FDA approval for EMPAVELI in C3G and IC-MPGN, November 2025 five-year GALE data indicating that SYFOVRE can meaningfully delay geographic atrophy progression over the long term, and February 2026 full-year 2025 results showing continued product revenue growth. SYFOVRE remained the company’s largest revenue driver, while EMPAVELI gained momentum following its renal expansion. Overall, Apellis offers investors exposure to a Nasdaq-listed United States biotech with meaningful commercial traction, a differentiated C3 platform, and ongoing clinical/regulatory catalysts.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
